|
|
Journal Articles / Abstracts
This information is intended for U.S. Healthcare Professionals only.
Articles
Following are selected journal articles pertaining to the use of COLAZAL® (balsalazide disodium) Capsules 750 mg in the treatment of mildly to moderately active ulcerative colitis. To review these articles, please click on the link to the PDF document and/or to the abstract for the article.
- Click here (PDF 1.52MB) to download the PDF version of: Green JR, Lobo AJ, Holdsworth CD. Balsalazide is more effective and better tolerated than Mesalamine in the treatment of Acute Ulcerative Colitis. Gastroenterology. 1998;114(1):15-22. (Posted 04/04)
- Click here (PDF 307KB) to download the PDF version of: Levine DS, M.D., Riff DS, M.D., Pruitt R, M.D. A Randomized, Double Blind, Dose-Response Comparison of Balsalazide (6.75 g), Balsalazide (2.25 g), and Mesalamine (2.4 g) in the Treatment of Active, Mild-to- Moderate Ulcerative Colitis. The American Journal of Gastroenterology. June 2002, Volume 97, Number 6.(Posted 04/04)
- Click here (PDF 159KB) to download the PDF version of: Pruitt R, M.D., Hanson J, M.D., Safdi M, M.D. Balsalazide is Superior to Mesalamine in the Time to Improvement of Signs and Symptoms of Acute Mild-to-Moderate Ulcerative Colitis. The American Journal of Gastroenterology. December 2002, Volume 12, Number 12. (Posted 04/04)
- Click here (PDF 78KB) to download the PDF version of: Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002;16(1):61-68. (Posted 10/02)
- Click here (PDF 83KB) to download the PDF version of: Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther. 2002;16(1):69-77. (Posted 10/02)
- Click here (PDF 65KB) to download the PDF version of: Ragunath K, Williams JG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001;15(10):1549-1554. (Posted 10/02)
- Click here (PDF 253KB) to download the PDF version of: Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, and The ABACUS Investigator Group. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther. 1998;12:1207-1216. (Posted 10/02))
- Click here (PDF 301KB) to download the PDF version of: Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001;49(6):783-789. (Posted 10/02)
- Click here (PDF 385KB) to download the PDF version of: Muijsers Richard BR, Goa Karen L. Balsalazide: A review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs. 2002; 62 (11):1689-1705. (Posted 10/02)
Get Adobe Acrobat Reader
COLAZAL® (balsalazide disodium) Capsules 750 mg are indicated for the treatment of mildly to moderately active Ulcerative Colitis in patients 5 years of age and older.
COLAZAL does not relieve symptoms in all patients; your patients' results may vary. In four well-controlled clinical trials, patients receiving a COLAZAL dose of 6.75g/day most frequently reported the following events
(reporting frequency > 3%): headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to
placebo. In the pediatric trial, patients most frequently reported the following adverse events: headache (15%), abdominal pain upper (13%), abdominal pain (12%), vomiting (10%), diarrhea (9%), colitis ulcerative (6%),
nasopharyngitis (6%) and, pyrexia (6%). COLAZAL is contraindicated in patients with a hypersensitivity to salicylates or the components of COLAZAL capsules or balsalazide metabolites. The safety and effectiveness of
COLAZAL beyond 8 weeks in children (ages 5-17 years) and 12 weeks in adults have not been established.
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email:
|
|